Introduction
At initial diagnosis, most bladder cancers (BCs) are nonmuscle-invasive (NMIBC). NMIBCs generally have a good prognosis if treated with transurethral resection (TUR) and adjuvant intravesical chemotherapy or BCG instillations [1] . However, NMIBCs invading the lamina propria, which are classified as T1-BC, progress to MIBC in 21-50% of cases.
Furthermore, 34% of patients with T1-BC die from this disease [2, 3] . These progression and mortality rates prove that T1-BC is a transition entity and add to the dilemma of whether to perform upfront radical cystectomy (RC), which is the standard for non-metastatic MIBC, or to apply conservative adjuvant intravesical treatment, as is the first choice for NMIBC.
In the search for criteria to optimise RC timing for NMIBC, several prognostic factors for progression have been identified. Apart from tumour stage, these include presence of carcinoma in situ (CIS) and, most importantly, tumour grade [4, 5] . The first grading system was adopted by the WHO in 1973 and divides urothelial-cell carcinomas in to Grades 1-3 [6] . In 2004, the WHO1973 grading system was replaced by a new classification. This classification identifies papillary urothelial neoplasia of low malignant potential (PUNLMP), low-grade (LG) and high-grade (HG) papillary urothelial carcinoma. The WHO2004 grading system divides tumours formally known as Grade 1 into PUNLMP and LG tumours. Grade 2 tumours were classified as either LG or HG, and all Grade 3 tumours as HG. Its purpose was to provide clear histological criteria and to decrease inter-observer variability, which was described to reach 50% [1] . However, thus far, no clear advantages of the WHO2004 grading system have been demonstrated [1, 7] . Therefore, the European Association of Urology (EAU) guidelines currently advise to use the WHO1973 and WHO2004 classifications simultaneously, because neither of them has been proven superior to the other [1] . The AUA guidelines recommend the WHO2004 classification as the most widely accepted and utilised grading system in the USA [8] . The aim of the present multicentre study was to compare the prognostic value of WHO1973 and WHO2004 grading systems in T1-BC.
Patients and Methods

Patients
Medical records and TUR slides of 601 patients treated for primary (first diagnosis) T1-BC in four university hospitals, between 1983 and 2010, were reviewed. This cohort included extended series from previously described individual studies [9, 10] . A second TUR was performed if muscularis propria was absent and/or the initial resection was incomplete. A standard re-TUR was not obligatory. Further treatment was initially conservative and consisted of at least one BCG induction cycle of six intravesical instillations. Follow-up included cystoscopic examination and urinary cytology every 3-4 months in the first 2 years, followed by every 6-12 months if disease did not recur. Progression was defined as tumour invasion of the muscularis propria (≥T2) and/or lymph node/visceral metastases on follow-up imaging. Progression-free survival (PFS) was defined as the time from initial TUR to progression or last progression-free follow-up.
Cancer-specific survival (CSS) was defined as time from initial TUR to death from disease or last follow-up.
Pathology Review
Tumours were confirmed to be T1, defined as invasion of BC into the lamina propria, at pathology review by six uropathologists in total. Next, two-centre pathology review of the TUR samples was performed (T.H.vdK. reviewed slides from Toronto, Paris and Rotterdam, n = 292, and A.H. reviewed slides from Regensburg, n = 309) for tumour grade according to the WHO1973 and 2004 classification systems in two separate rounds. Furthermore, samples from Rotterdam (n = 66) were reviewed twice by T.H.vdK. and G.J.L.H.vL. for each grading system, enabling intra-and interobserver variation analyses. Each pathologist was blinded to the clinical data, apart from the original T1 diagnosis. Samples were graded according to the WHO1973 classification as Grade 1-3 and according to the WHO2004 classification as PUNLMP, LG or HG.
Statistics
Tumour grade according to both classifications were individually correlated with other baseline characteristics using Pearson chi-squared tests (sex, tumour focality, tumour size, and concomitant CIS) and Mann-Whitney U-test (age). PFS and CSS were estimated with the Kaplan-Meier method. PFS and CSS were individually compared between tumour grades defined according to both the WHO1973 and WHO2004 classifications with a log-rank test and Cox regression analysis. On multivariable analysis, we corrected for patient age, sex, tumour focality, year of diagnosis, tumour size (>3 vs ≤3 cm) and concomitant CIS. Year of diagnosis was categorised according to the following time frames: 1983-1990, 1991-2000 and 2001-2010 
Results
Baseline tumour and patient characteristics are shown in Table 1 . According to the WHO1973 system, 188 (31%) tumours were classified as Grade 2 and 413 (69%) were Grade 3. None of the slides were Grade 1. According to the WHO2004 system, 554 (92%) tumours were HG, whilst 47 (8%) were LG. None of the slides were classified as PUNLMP. Grade 3 tumours more often had concomitant CIS (40%) than Grade 2 tumours (17%, P < 0.001). Likewise, TUR specimens of HG tumours showed CIS more often (34%) than LG specimens (19%, P = 0.040). None of the other baseline characteristics were significantly correlated with either of the two WHO classifications (data not shown).
The median (interquartile range [IQR]) follow-up was 5.9 (3.3-9.0) years for patients alive at last follow-up. During follow-up, 148 (25%) patients progressed to MIBC and 142 (24%) underwent RC. Progression rates at 5 years of followup for WHO1973 and 2004 are shown in Table 2 . Patients with Grade 3 tumours had worse PFS than patients with Grade 2 tumours on univariable (hazard ratio [HR] 2.1, 95% CI 1.4-3.2; P < 0.001; Fig. 1a ) and on multivariable analysis (Table 3 ). In univariable analyses for progression, CIS (P = 0.029) and multifocality (P = 0.041) were significant, whilst size (P = 0.060) showed a tendency towards significance. WHO1973 grade was the only prognostic variable for progression on multivariable analysis ( Table 3 ). The WHO2004 system was not prognostic for PFS on univariable (HG vs LG; HR 1.98, 95% CI 0.9-4.2; P = 0.077; Fig. 1b ) or multivariable analysis (Table 3) . Adding the WHO2004 classification to the multivariable WHO1973 Coxregression model did not improve the prognostic value of the model (À2log likelihood 1688.1 vs 1688.2, P = 0.821). Of note, year of T1-BC diagnosis was not significantly associated with PFS (P = 0.239).
In total, 205 (34%) patients died during follow-up, of which 94 (16%) patients died from BC. CSS at 5 years of follow-up was 78% for patients with Grade 3 disease vs 96% for Grade 2 disease (P < 0.001, Fig. 1c ). This difference was also significant on multivariable analysis (HR 3.2, 95% CI 1.7-5.7; P < 0.001; Table 4 ). In univariable analyses for CSS, CIS (P = 0.003), size (P = 0.001), age (P < 0.001) and multifocality (P = 0.030) were also significant. Additional prognostic factors for worse CSS in multivariable analysis were tumour size >3 cm and older patient age (Table 4) . According to the WHO2004 classification, the 5-year CSS was 83% for HG tumours vs 93% for LG tumours (P = 0.292, Fig. 1d ). This difference was not statistically significant on multivariable analysis (HR 1.5, 95% CI 0.62-3.8; P = 0.368) or univariable analysis (P = 0.287). Again, adding WHO2004 grade to the WHO1973 model did not improve its prognostic value (À2log likelihood 1022.8 vs 1024.0, P = 0.272). CSS was not significantly associated with year of T1-BC diagnosis (P = 0.271). RC was performed in 142 (24%) patients. Patients with progression aged >70 years were less likely to receive a RC than patients ≤70 years (43% vs 69%, P = 0.002). On multivariable analysis, predictors for receiving RC were lower age (age coefficient estimate; CE 0.95, P < 0.001), CIS (CE 2.0, P = 0.006) and progression (CE 7.1, P < 0.001).
Intra-observer reproducibility, assessed for the 66 cases from Rotterdam, was almost perfect for WHO1973 (j 0.79-0.90) and moderate to substantial for WHO2004 classification (j 0.40-0.67). Inter-observer reproducibility ranged from moderate to substantial for both classification systems (WHO1973; j 0.31-0.55 and WHO2004; j 0.23-0.41). Additionally, the proportion of LG and Grade 2 tumours varied significantly amongst hospitals (Table 5 ). Despite this difference in grade distributions, results regarding the prognostic value of the grading classifications were consistent for all cohorts. WHO1973 was either a significant or borderline significant prognosticator for progression (Rotterdam cohort borderline) and CSS (Toronto, Paris and Rotterdam cohorts individually borderline), whereas WHO2004 was not prognostic in any cohort (data not shown). Patients at risk Grade 2 Grade 3 Fig. 1 The median follow-up for the 601 primary T1 urothelial bladder tumours was 5.9 years. PFS was grouped according to (a) the WHO1973 classification (Grade 2 vs 3, log-rank test P < 0.001) and according to (b) the WHO2004 (LG vs HG, log-rank test P = 0.077) classification. CSS was grouped according to (c) the WHO1973 classification (Grade 2 vs 3, log-rank test P < 0.001) and according to (d) the WHO2004 classification (LG vs HG, log-rank test P = 0.292).
© 2018 The Authors BJU International © 2018 BJU International 981 Discussion T1-BC is a distinctive NMIBC entity with a high risk of progression [2, 3] . Prognosis greatly depends on tumour grade. However, this prognostic value is based on studies using the WHO1973 grading system, while the WHO currently recommends the use of the 2004 system [4, 5, 7] . To our knowledge, the present study is the largest multicentre study thus far to compare both classification systems for grade in T1-BC. In our present cohort, 25% of patients progressed to MIBC and 16% died from BC. This emphasises the potentially lethal nature of T1-BC and the urgent need for robust prognosticators. Our present results demonstrated that the WHO1973 classification is highly prognostic in T1-BC, whereas the WHO2004 classification is not. Consequently, our present results indicate that WHO1973 grade cannot be replaced by the WHO2004 classification in clinical NMIBC guidelines.
The lack of prognostic value of the WHO2004 classification is most likely due to a lower number of T1-LG tumours, which resulted in a nearly one-tiered grading system (T1-LG, n = 47, 8% vs T1-Grade 2, n = 188, 31%). The criteria defined by the WHO in 2004 are most likely the cause for the shift of many Grade 2 cases to HG. Research groups participating in the present study have already had similar results in previous individual reports. Otto et al. [9] described a T1-LG rate of 4% in their single centre cohort, whilst van Rhijn et al. [10] reported 19% T1-LG tumours in their two-centre cohort. Neither found any prognostic value for the 2004 classification [9, 10] . However, their results could have been compromised by limited power due to relatively small sample sizes (van Rhijn et al. [10] n = 134, Otto et al. [9] n = 310). This is reflected by the fact that van Rhijn et al. [10] did not find the WHO1973 system to be of prognostic value either. Other retrospective series have similarly failed to show prognostic value for the WHO2004 system in T1-BC, although all suffered from relatively small sample sizes (n = 68-183) and none compared its prognostic value with WHO1973 [11] . The present findings in a large population among four academic hospitals confirm the ineffectiveness of the WHO2004 classification in T1-BC. On the contrary, WHO1973 has been reported a prognosticator for progression and CSS in several larger T1-BC cohorts (n = 166-587) [9, 12, 13] . These included only one comparative study by Otto et al. [9] , who, as previously mentioned, did not find the WHO2004 system to be of prognostic value. It has been suggested that the three-tiered 1973 system is disadvantageous in T1-BC, because T1-Grade 1 BC does not exist [9, 12] . Indeed, we did not identify any Grade 1 tumours, which virtually turned the 1973 classification in a two-tiered grading system with most of the T1-BCs being Grade 3 (69%). Nevertheless, in our present cohort the WHO 1973 classification proved prognostic for progression and CSS in all our cohorts.
We did not identify any other prognosticators for progression than WHO1973 grade. In NMIBC in general, predictors for progression other than stage and grade are presence of concomitant CIS and recurrence at first cystoscopy [4, 5] . In our present cohort, concomitant CIS was associated with both higher WHO1973 and WHO2004 grade and clinical outcome on univariable analyses. It is most likely that this has reduced the prognostic value of CIS to non-significant on multivariable analysis. As our present aim was to identify prognosticators at initial diagnosis, we could not investigate the prognostic value of recurrence at first cystoscopy. Likewise, we did not include the number of BCG instillations in our multivariable analysis because this is, even more than recurrence at first cystoscopy, an indirect outcome measure of progression and survival. In our present study, additional prognostic factors for CSS were tumour size >3 cm and patient age. The prognostic role for size was recently confirmed in a large international retrospective study with 2 451 patients and a meta-analysis involving 15 215 patients [14, 15] . The negative impact of age on CSS in the present study is remarkable. Previous literature has suggested that elderly patients have a poor immunological response to intravesical BCG therapy for NMIBC [16] . However, this theory is not probably the prominent explanation for our present findings because age was only associated with CSS and not associated with a higher risk of progression in our cohort. Rather, our present results suggest that elderly patients received less effective treatment if progression occurred. A recent population-based analysis from the USA showed that, although RC use in elderly patients is increasing, still only 24% of patients with MIBC aged >75 years receive RC [17] . The lower odds for older patients to receive RC were independent of comorbidity. Although we could not account for comorbidity, we also observed that increasing age was associated with lower odds of RC. We reported RC treatment in 43% of patients with progression aged >70 years. This strengthens the hypothesis that urologists are hesitant in performing major surgery in elderly patients.
Intra-observer variability appeared to be more favourable for WHO1973 than WHO2004 in our present exploratory analyses using the Rotterdam cohort (n = 66). Inter-observer reproducibility was only moderate to substantial for both WHO classification systems. Our observer variability in T1-BC is consistent with results reported in previous literature on NMIBC [1, 18, 19] . Despite the description of histological criteria in the WHO2004 classification, studies thus far including the present one, have not reported a clear improved reproducibility of WHO2004 over the WHO1973 system [1, [18] [19] [20] . Hence, our present results on reproducibility in T1-BC also oppose the replacement of WHO1973 by the 2004 classification. In addition, the differences in the distribution of tumour grades for both classification systems, as shown in Table 5 , are most likely the effect of mean grade differences between the two pathologists (T.H.vdK. and A.H.) involved in this review [19] .
Our present study is limited by several factors. First, our cohort comprises a long period of inclusion. Consequently, patients did not receive a standard re-TUR, which is now recommended in T1-BC treatment [1, 8] . However, we did correct for a complete TUR and muscle in the specimen to reduce the heterogeneity of our study cohort. Of note, Gontero et al. [21] recently reported in a large study involving 2 451 patients that a standard re-TUR did not reduce risk of progression or improve CSS in patients with muscle in the specimen and a complete TUR. Secondly, the same pathologists evaluated the slides according to both the WHO1973 and 2004 classification systems and could therefore theoretically have been biased. However, we expect this effect to be minimal because pathologists graded the slides in two separate rounds and were blinded for all clinical data. In addition, we did not perform a central pathology review for all cases. However, we believe that, given the results of the review of the two uro-pathologists with~300 cases per pathologist and the additional reviews of the Rotterdam cohort to assess intra-and inter observer variability for WHO1973 and WHO2004, a formal central review would not change the most important message of our present study that WHO1973 is preferred over WHO2004 for T1-BC prognostics. Subdivision of the micro-invasive component in T1-BC seems to have prognostic significance in several studies [2, 10, 15] and has recently been adopted as an option by clinical guidelines [1] . Further study of pathological T1 sub-stage against established variables may prove its additional value next to, e.g., tumour grade. Strengths of our present study include the large sample size, the multicentre and international setting, and the fact that all patients had primary T1-BC and were initially conservatively treated with intravesical BCG.
In the past, attempts to improve NMIBC prognostication have resulted in combining the WHO1973 and the later adopted WHO2004 classifications into a four-tiered system. This classification was recommended by the WHO in 1999 [22] . The WHO1999 has better defined criteria than WHO1973. Furthermore, the WHO1999 combines the advantages of the WHO1973 and WHO2004 in NMIBC in general, without loss of stage categories in T1-BC specifically. However, a theoretical limitation is the increase in observer variability inherent to the addition of a fourth grade category. Although the WHO1999 system carried prognostic value in a few studies [12, 23] , it has not been widely adopted, nor implemented in clinical guidelines [1, 8] . In our present T1-BC cohort, WHO2004 had no prognostic value, whereas WHO1973 was a strong prognosticator for progression and CSS. Our present results indicated that WHO1973 grade may be a useful tool in decision-making for the management of patients with T1-BC. Combining the WHO1973 and WHO2004 systems did not significantly alter the prognostic value as opposed to applying the WHO1973 alone, which suggests that the WHO1999 may be used in T1-BC with similar prognostic accuracy as the WHO1973. Nevertheless, the WHO2004 grading system cannot replace the WHO1973 system as a prognosticator in T1-BC, nor can tumour grade be neglected in the management of T1-BC. Therefore, based on the currently available evidence, we believe that the WHO1973 system should still be recommended by clinical NMIBC guidelines, provided that clinicians use this grading system for decisions regarding T1-BC patient management.
